No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
Preparation of orally disintegrating tablets from active ingredients of citrus peel by direct powder compression for the maintenance of brain function
Abstract
Citrus kawachiensis peel (PCK), a new functional food material, may prolong the healthy life expectancy of aging populations. Tableting PCK could facilitate its worldwide distribution and consumption. A PCK dosage form that is easy to swallow should be prepared for ease of use by the elderly. We investigated the fabrication of orally disintegrating (OD) tablets with the required commercial strength and disintegration time. We formulated OD tablets comprising PCK powder, crospovidone, vinylpyrrolidone vinyl acetate copolymer, light anhydrous silicic acid, D-mannitol, and magnesium stearate. The tablets were prepared using a rotary tableting press. Tableting was optimized by setting the target hardness to 30−50 N and target disintegration time to ≤ 2 min. When tableting was performed at a compression pressure of 7.5 kN, the hardness was 40 N and disintegration time was 1.5 min. The OD tablet containing a high proportion of PCK possessed the properties preferred and required for commercial products.
... Their particles have complex shapes, low flowability and high cohesion, preventing mass uniformity of compacts. Furthermore, when such materials are subjected to compaction forces they show poor tablet-ability, reflected on insufficient hardness or lower disintegration times and ability to release the therapeutically active components promoting the manufacture of poor quality [39]. The poor flowability shown by DVR particles (F2, angle of repose = 36⁰ and high Carr's index = 15.7, ...
The Diospyros villosa root extract (DVR) has the potential to treat oral cavity diseases (DOC), as confirmed by its frequent use as a toothbrush among Mozambicans. In the present work, a tablet with adhesive properties was developed with properties that have the potential to overcome the expected difficulties in delivering the drug into the oral cavity. The chemical profile of the extract marker secondary metabolites was established by TLC and LC-UV/DAD, and the quantification of its main classes was performed by UV and IR spectrophotometries. The size of the particles of the extract was determined by laser diffractometry. The tablets manufactured were evaluated to confirm the extract chemical stability based on the major marker secondary metabolite profile, throughout processing (differential scanning calorimetry, DSC and Fourier transform infrared spectroscopy, FTIR) and their performance based on adhesion forces (i.e., force required to remove a tablet from a flat surface) and for their ability to release the main marker secondary metabolites (dissolution test). The study has shown that the use of colloidal silica in the preparation of the extract delivered a powder containing particles with improved flow and by adding an adhesive polyacrylic acid derivative to the composite extract particles it was possible to obtain a blend enabling the manufacture of adhesive tablets by direct compression. Overall, the study demonstrated the ability to produce DVR-containing adhesive tablets for buccal use against DOC.
We previously reported that the subcutaneous administration of 3,5,6,7,8,3′,4′-heptamethoxyflavone (HMF), a citrus polymethoxyflavone, attenuated depressive-like behavior and increased the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus of a corticosterone-induced depression-like mouse model. We herein demonstrated that (1) HMF was detectable in the brain 10 and 30 min after its oral administration, (2) orally administered HMF improved chronic unpredictable mild stress (CUMS)-induced pathological conditions, including body weight loss and depressive-like behavior, and CUMS-induced neurochemical changes, such as reduction in BDNF expression, decrease in neurogenesis, and decreased level of phosphorylated calcium-calmodulin-dependent protein kinase II in the hippocampus, and (3) these effects of HMF were inhibited by the pre-administration of U0126, a mitogen-activated protein (MAP) kinase inhibitor. These results suggest that orally administered HMF is beneficial for the upregulation of BDNF in the hippocampus via the extracellular signal-regulated kinase1/2 (ERK1/2)/MAP system, which may account for its antidepression effects.
The study evaluates use of Kollidon VA(®) 64 and a combination of Kollidon VA(®) 64 with Kollidon VA(®) 64 Fine as excipient in direct compression process of tablets. The combination of the two grades of material is evaluated for capping, lamination and excessive friability. Inter particulate void space is higher for such excipient due to the hollow structure of the Kollidon VA(®) 64 particles. During tablet compression air remains trapped in the blend exhibiting poor compression with compromised physical properties of the tablets. Composition of Kollidon VA(®) 64 and Kollidon VA(®) 64 Fine is evaluated by Design of Experiment (DoE). A Scanning Electron Microscopy (SEM) of two grades of Kollidon VA(®) 64 exhibits morphological differences between coarse and fine grade. The tablet compression process is evaluated with a mix consisting of entirely Kollidon VA(®) 64 and two mixes containing Kollidon VA(®) 64 and Kollidon VA(®) 64 Fine in ratio of 77:23 and 65:35. A statistical modeling on the results from the DoE trials resulted in the optimum composition for direct tablet compression as combination of Kollidon VA(®) 64 and Kollidon VA(®) 64 Fine in ratio of 77:23. This combination compressed with the predicted parameters based on the statistical modeling and applying main compression force between 5 - 15 kN, pre-compression force between 2 - 3 kN, feeder speed fixed at 25 rpm and compression range of 45 - 49 rpm produced tablets with hardness ranging between 19 - 21 kp, with no friability, capping or lamination issue.
In patients with Parkinson’s disease (PD), hyperactivated inflammation in the brain, particularly microglial hyperactivation in the substantia nigra (SN), is reported to be one of the triggers for the delayed loss of dopaminergic neurons and sequential motor functional impairments. We previously reported that (1) auraptene (AUR), a natural prenyloxycoumain, suppressed inflammatory responses including the hyperactivation of microglia in the ischemic brain and inflamed brain, thereby inhibiting neuronal cell death; (2) 7-isopentenyloxycoumarin (7-IP), another natural prenyloxycoumain, exerted anti-inflammatory and neuroprotective effects against excitotoxicity; and (3) 4′-geranyloxyferulic acid (GOFA), a natural prenyloxycinnamic acid, also exerted anti-inflammatory effects. In the present study, using an intranigral lipopolysaccharide (LPS)-induced PD-like mouse model, we investigated whether AUR, 7-IP, and GOFA suppress microglial activation and protect against dopaminergic neuronal cell death in the SN. We successfully showed that these prenyloxyphenylpropanoids exhibited these prospective abilities, suggesting the potential of these compounds as neuroprotective agents for patients with PD.
In the present study, a microwave treatment process has been applied to prepare orally disintegrating tablets (ODTs) containing powdered tea leaves with enriched levels of the anti-inflammatory compounds such as chafuroside A (CFA) and chafuroside B (CFB). The use of distilled water as the adsorbed and granulation solvents in this preparation process afforded tablets with a long disintegration time (more than 120 s). The CFA and CFB contents of these tablets did not also change after 4 min of microwave irradiation due to the tablet temperature, which only increased to 100°C. In contrast, the tablet temperature increased up to 140°C after 3 min of microwave irradiation when a 1.68 M Na2HPO4 solution instead of distilled water. Notably, the disintegration time of these tablets was considerably improved (less than 20 s) compared with the microwave-untreated tablets, and there were 7- and 11-fold increases in their CFA and CFB contents. In addition, the operational conditions for the preparation of the tablets were optimized by face-centered composite design based on the following criteria: tablet hardness greater than 13 N, disintegration time less than 30 s and friability less than 0.5%. The requirements translated into X1 (the amount of granulation solvent), X2 (tableting pressure) and X3 (content of the powdered tea leaves) values of 45%, 0.43 kN and 32%, respectively, and the ODTs containing powdered tea leaves prepared under these optimized conditions were found to show excellent tablet properties and contain enriched levels of CFA and CFB.
We have recently shown that 3,5,6,7,8,3#x2032;,4#x2032;-heptamethoxyflavone (HMF) and auraptene (AUR) have neu-roprotective effects on the central nervous system. HMF, a citrus flavonoid, altered NMDA-type glutamate receptor antagonist MK-801-induced memory dysfunction and schizophrenia-positive symptom-like behavior. HMF also showed a protective effect against ischemia-induced short-term memory dysfunction. In the ischemic brain, HMF induced the following protective effects against brain dysfunction: 1) rescue of neuronal cell death in the hippocampus; 2) increased production of brain-derived neurotrophic factor; 3) stimulation of neurogenesis in the dentate gyrus subgranular zone; 4) activation of the autophosphorylation of calcium—calmodulin-dependent protein kinase II; and 5) suppression of microglial activation. On the other hand, AUR, a citrus coumarin, ameliorated lipopolysaccharide-induced inflammation in the brain as shown by inhibition of microglial activation and inhibition of cyclooxygenase (COX) -2 expression in the hippocampus. AUR also showed antiinflammatory effects on the ischemic brain by inhibiting microglial activation, COX-2 expression, and neuronal cell death in the hippocampus. The peel of kawachibankan (Citrus kawachiensis),a noted citrus product of Ehime prefecture, Japan, contains AUR, HMF, naringin, and narirutin. The dried powder of both the peel and juice had antiinflammatory effects in the mouse hippocampus, suggesting that citrus compounds may be beneficial as neuroprotective agents in the treatment of neurological disorders.
Examination of the dried peel powder of Citrus kawachiensis, one of the citrus products of Ehime, Japan, showed that it contained naringin (NGIN; 44.02 ± 0.491 mg/g), narirutin (NRTN; 4.46 ± 0.0563 mg/g), auraptene (AUR; 4.07 ± 0.033 mg/g), and 3,5,6,7,8,3',4'-heptamethoxyflavone (HMF; 0.27 ± 0.0039 mg/g). When this dried peel powder was orally preadministered at the dose of 1.2 or 2.4 g/kg/day for 7 days into lipopolysaccharide- (LPS-) injected mice, an animal model of systemic inflammation, it suppressed (1) LPS-induced loss of body weight and abnormal behavior in the open field, (2) LPS-induced activation of microglia and astrocytes in the hippocampus, and (3) LPS-induced expression of cyclooxygenase (COX)-2, which were coexpressed in astrocytes of these mice. When NGIN or AUR was preadministered to LPS-injected mice at an amount similar to that in the peel powder, AUR, but not NGIN, had the ability to suppress the LPS-induced inflammation in the brain of these model mice. The dried powder of flavedo tissue (the outer colored layer of the mesocarp of a citrus fruit) and juice, which contained sufficient amounts of AUR, also had anti-inflammatory effect. These results suggest that AUR was the main ingredient responsible for the anti-inflammatory property of the dried peels of C. kawachiensis.
The technologies used for developing orally disintegrating tablets: A review
Orally disintegrating tablets (ODTs), also known as fast melts, quick melts, fast disintegrating and orodispersible systems, have the unique property of disintegrating in the mouth in seconds without chewing and the need of water and are thus assumed to improve patient compliance. Conventional methods like direct compression, wet granulation, moulding, spray-drying, freeze-drying and sublimation were used to prepare ODTs. New advanced technologies like Orasolv®, Durasolv®, Wowtab®, Flashtab®, Zydis®, Flashdose®, Oraquick®, Lyoc®, Advatab®, Frosta®, Quick-Disc® and Nanomelt® have been introduced by some pharmaceutical companies for the production of ODTs. The main objective of this review is to give a comprehensive insight into conventional and recent technologies used for the preparation of ODTs.
The purpose of the current study was to mask the taste of cetirizine HCl and to incorporate the granules produced in oral disintegrating tablets (ODT). The bitter, active substance was coated by fluidized bed coating using Eudragit® RL30-D at levels between 15% and 40% w/w. The ODTs were developed by varying the ratio of superdisintegrants such as sodium croscarmellose, crospovidone grades and low substituted hydroxypropyl cellulose (L-HPC). A direct compression process was used to compress the ODTs under various compaction forces to optimize tablet robustness. The properties of the compressed tablets including porosity, hardness, friability and dissolution profiles were further investigated. The in vitro and in vivo evaluation of the tablet disintegration times showed almost identical rapid disintegration below 10 s at the optimal levels of each superdisintegrant. Finally, the taste and sensory evaluation in human volunteers demonstrated excellence in masking the bitter active and tablet palatability.
Orally disintegrating systems have carved a niche amongst the oral drug delivery systems due to the highest component of compliance they enjoy in patients especially the geriatrics and pediatrics. In addition, patients suffering from dysphagia, motion sickness, repeated emesis and mental disorders prefer these medications because they cannot swallow large quantity of water. Further, drugs exhibiting satisfactory absorption from the oral mucosa or intended for immediate pharmacological action can be advantageously formulated in these dosage forms. However, the requirements of formulating these dosage forms with mechanical strength sufficient to with stand the rigors of handling and capable of disintegrating within a few seconds on contact with saliva are inextricable. Therefore, research in developing orally disintegrating systems has been aimed at investigating different excipients as well as techniques to meet these challenges. A variety of dosage forms like tablets, films, wafers, chewing gums, microparticles, nanoparticles etc. have been developed for enhancing the performance attributes in the orally disintegrating systems. Advancements in the technology arena for manufacturing these systems include the use of freeze drying, cotton candy, melt extrusion, sublimation, direct compression besides the classical wet granulation processes. Taste masking of active ingredients becomes essential in these systems because the drug is entirely released in the mouth. Fluid bed coating, agglomeration, pelletization and infusion methods have proven useful for this purpose. It is important to note that although, freeze dried and effervescent disintegrating systems rapidly disintegrate in contact with fluids, they do not generally exhibit the required mechanical strength. Similarly, the candy process cannot be used for thermolabile drugs. In the light of the paradoxical nature of the attributes desired in orally disintegrating systems (high mechanical strength and rapid disintegration), it becomes essential to study the innovations in this field and understand the intricacies of the different processes used for manufacturing these systems. This article attempts at discussing the patents relating to orally disintegrating systems with respect to the use of different formulation ingredients and technologies.
We previously reported that the dried peel powder of Citrus kawachiensis exerted anti-inflammatory effects in the brain in several animal models. Hyperglycemia induces inflammation and oxidative stress and causes massive damage in the brain; therefore, we herein examined the anti-inflammatory and other effects of the dried peel powder of C. kawachiensis in the streptozotocin-induced hyperglycemia mice model and in the type 2 diabetic db/db mice model. The C. kawachiensis administration inhibited microglial activation in the hippocampus in the streptozotocin-injected mice. Moreover, The C. kawachiensis treatment inhibited astroglial activation in the hippocampus and the hyperphosphorylation of tau at 231 of threonine and 396 of serine in hippocampal neurons, and also relieved the suppression of neurogenesis in the dentate gyrus of the hippocampus in the db/db mice. It was suggested that the dried peel powder of C. kawachiensis exerts anti-inflammatory and neuroprotective effects in the brain.
In a previous study, we reported that interleukin-4 production was reduced in spleen cells of mice administered 3,5,6,7,8,3',4'-heptamethoxyflavone (HMF), which is a polymethoxyflavone found at high concentrations in the peel of various citrus fruits. In this study, we investigated the function of HMF on the growth of T cells cultured from the spleens of mice. HMF decreased the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by anti-CD3/CD28 antibody-stimulated mouse spleen cells. HMF inhibited the activities of phosphodiesterase (PDE) enzymes prepared from bovine brain and human PDE4B and PDE3B enzymes. The cyclic AMP (cAMP) content in anti-CD3/CD28 antibody-stimulated spleen cells increased after HMF treatment in vitro. These results suggest that HMF inhibits T-cell growth and affects immune function via reduced PDE activity and increased cAMP content.
The compacting properties of powdered herbal plant, Pellodendron Bark (Obaku) to prepare themore convenient dosage form, tablet, than the usual commercial product. The tablet hardness was highly dependent on the particle size of the powdered harbal plant. Formulating some disintegrant such as calcium carboxymethyl cellulose effectively improved the disintegration property of resultant tablet. However, the tablet hardness was decreased by formulating the disintegrant powder. Adding a small amount of fine silica particles in the formulation increased the tablet hardness. The spray-dried extract powder and crude plant powder of Pellodendron Bark showed the different tendency in designing the optimum tablet formulation in the point of hardness and disintegration property. By measuring the compacting properties of the powder formulations, it was suggested that change in plastic property of the powder bed was not the main reason to improve the compacting property of the formulation.
Orally disintegrating tablets (ODTs) are currently widely used in drug therapy and are clinically attractive, because they are suitable for administration to patients with dysphagia and improve adherence, both of which increase the possibility of achieving the expected therapeutic effect. These properties of ODTs, which increase treatment effectiveness, are termed their “clinical functionality”, and ODTs with a high clinical functionality are required to meet the increasing need for these tablets. For example, there is a need for development of a clinically effective ODT with superior disintegrating properties while maintaining high tablet strength, bioequivalence with normal tablets while masking the bitterness with a fine particle coating, and a disintegration mechanism while maintaining moisture resistance and good storage quality. Thus, next-generation ODTs that overcome these conflicting properties, “trade-offs”, will be developed, using innovative formulation research technology. In this symposium, we will discuss a next-generation OD formulation known as PLETAAL OD, a high-dose antiplatelet agent, and will present the results of validation tests performed in our laboratory pertaining to high tablet strength, superior disintegration property, high wicking capacity, and storage stability with high moisture resistance. We will also introduce a second-generation antihistamine ALLELOCK OD and discuss its high clinical functionality achieved by masking the bitterness and obtaining bioequivalence with normal tablets by using granules while maintaining high tablet strength with EXLUB and SOLBLET technology.
The granulation from mixed crude drug powders was carried out by fluidized bed and agitation methods. The effects of the physical properties of the binder solution, such as the contact angle on the powder compact, the viscosity, on the granule characteristics, the average granule size, angle of repose, bulk density, granule strength, compressibility, and strength of compact, were examined.Correlation between the physical properties of the products obtained by fluidized bed granulation and agitation granulation, and those of the binder solution were analysed by using the correlation formula derived from multiple regression analysis. A highly confident multiple correlation was found and the relationship between physical properties of the binder solution and those of the granules can be expressed quantitatively.It suggests the possibility that formulation of powder materials for production of granules having desirable physical properties can be easily determined and, also, the granulating manipulation which has been performed experimentally or qualitatively, can be done quantitatively and rationally, by using the results.
Fifteen constituents, including a new compound, were isolated from an ethanolic extract of the peel of Citrus kawachiensis Hort. ex. Y. Tanaka (Japanese brand name, kawachibankan) which is one of the citrus products specific to Ehime, Japan. The new compound was characterized as 4'-dihydrophaseic acid β-glucopyranose ester (15) on the basis of spectral and chemical evidence.
Purpose:
To overcome the limitation of insufficient hardness during the production of rapidly disintegrating orally dispersible tablets (ODTs). Furthermore, we investigated the properties and usefulness of functionalized calcium carbonate (FCC) as a new pharmaceutical excipient for the production of ODTs.
Methods:
A highly sensitive tensiometer-based method was developed to measure kinetics of weight loss during tablet disintegration. With this method we were able to determine the residence time of tablets placed on a basket immersed into a test medium. The shapes of tensiometer plots allowed us to categorize substances into four different types of disintegration.
Results:
At the same volume and hardness, the tablet formulations with FCC showed a significantly higher porosity (over 60%) than all other formulations. Residence time depended mainly on the tablet composition rather than on porosity. When combined with disintegrants, FCC formulations exhibited favorable disintegration properties, comparable to those of the marketed drug risperidone oro (disintegration time ca. 10 s).
Conclusions:
Oral dosage forms--based on the new pharmaceutical excipient FCC--can be designed to have a short disintegration time combined with good mechanical strength. Due to these properties, FCC can be used for the preparation of ODTs.
Orally disintegrating tablets (ODTs) offer many advantages over the conventional oral dosage forms in terms of convenience and ease of use. Over the last decade, substantial advances in the formulation of ODTs have been achieved in academia and industry that resulted in the emerging of a large number of patents. The aim of this review is to summarise the most recent patents in ODT formulations and highlight their motivations, inventive steps and significances in the development of ODT formulations. Five major techniques have been applied in manufacturing of ODTs, namely conventional tablet press, moulding, freeze drying, tablet loading and pulverization, with majority of the patents dedicated to the use of conventional tablet pressing. The patents have addressed various issues concerning the manufacturing of robust and practical ODT formulations by disclosing new manufacturing techniques, advantageous materials, and innovative formulation steps. However, future developments are required to reduce the cost and widening the application of the new manufacturing techniques, while simplifying and shortening the formulation steps will be crucial in the well established ones.
The aim of this study was to design a new orally disintegrating tablet (ODT) that has high tablet hardness and a fast oral disintegration rate using a new preparation method. To obtain rapid disintegration granules (RDGs), a saccharide, such as trehalose, mannitol, or lactose, was spray-coated with a suspension of corn starch using a fluidized-bed granulator (suspension method). As an additional disintegrant, crospovidone, light anhydrous silicic acid, or hydroxypropyl starch was also included in the suspension. The RDGs obtained possessed extremely large surface areas, narrow particle size distribution, and numerous micro-pores. When tabletting these RDGs, it was found that the RDGs increased tablet hardness by decreasing plastic deformation and increasing the contact frequency between granules. In all tablets, a linear relationship was observed between tablet hardness and oral disintegration time. From each linear correlation line, a slope (D/H value) and an intercept (D/H(0) value) were calculated. Tablets with small D/H and D/H(0) values could disintegrate immediately in the oral cavity regardless of the tablet hardness and were considered to be appropriate for ODTs. Therefore, these values were used as key parameters to select better ODTs. Of all the RDGs prepared in this study, mannitol spray-coated with a suspension of corn starch and crospovidone (2.5:1 w/w ratio) showed most appropriate properties for ODTs; fast in vivo oral disintegration time, and high tablet hardness. In conclusion, this simple method to prepare superior formulations for new ODTs was established by spray-coating mannitol with a suspension of appropriate disintegrants.
The dry binding activity of copolyvidone (Kollidon VA 64), povidone (Kollidon 30), microcrystalline cellulose (Avicel PH-101), hydroxypropylmethylcellulose (HPMC) 2910 (Pharmacoat 606), and maltodextrin (Maldex 18) was investigated using a variety of formulations and methods. The effect of the dry binders in direct tableting and compaction was studied using a dicalcium phosphate formulation (water-insoluble ingredients) and a vitamin C formulation (water-soluble ingredients) applying three compression forces. The binder content was varied between 5% and 15% in both formulations, and the tablet properties were determined. All the tablets showed an improvement in mechanical properties (hardness, friability) with increasing dry binder concentration, with Kollidon VA 64 showing by far the greatest binding efficacy. A significant influence (prolongation) on drug release was observed only with HPMC 2910. The drying binding properties were analyzed for correlations with various powder and material properties. Especially, particle size, surface/surface structure, and plasticity were found to influence binding activity. The ideal dry binder should have small particles, high plasticity, and a large surface area.
The purpose of this study was to investigate the influence of roller compaction parameters on granule and tablet quality of a dry herbal extract from St. John's wort (Hypericum perforatum L.), which is widely used in the treatment of mild to moderate depressive disorders. Eight different extract batches were blended with 0.5, 2, and 5% of magnesium stearate and were compacted at different compaction forces using a gap width and force controlled roller compactor. The ribbon formed was milled into granules having mean particle sizes up to 700 microns. The roller compaction of the extracts decreased significantly the angle of repose from about 45 to 32 degrees and the Hausner ratio from about 1.2 to 1.1. Tabletting of granulated extract instead of extract powder effectively reduced not only dust and feeding problems during the tabletting process but also prevented capping. The incorporation of 2 and 5% of magnesium stearate into the roller compacted extract reduced significantly the sticking of the dry herbal extracts to the punch faces without affecting the crushing strength of the tablets. Tablets containing granulated extracts exhibited a 3-fold lower disintegration time of about 12 min compared to tablets containing extract powder. Dissolution studies revealed that hyperforin, hypericin, and rutin were more rapidly released from tablets containing granulated extract. Therefore, roller compaction leveled out the differences in technological properties between the eight dry herbal extracts and compression of granulated extract significantly improved tablet quality.
Fast disintegrating tablets (FDTs) have received ever-increasing demand during the last decade, and the field has become a rapidly growing area in the pharmaceutical industry. Upon introduction into the mouth, these tablets dissolve or disintegrate in the mouth in the absence of additional water for easy administration of active pharmaceutical ingredients. The popularity and usefulness of the formulation resulted in development of several FDT technologies. This review describes various formulations and technologies developed to achieve fast dissolution/dispersion of tablets in the oral cavity. In particular, this review describes in detail FDT technologies based on lyophilization, molding, sublimation, and compaction, as well as approaches to enhancing the FDT properties, such as spray-drying, moisture treatment, sintering, and use of sugar-based disintegrants. In addition, taste-masking technologies, experimental measurements of disintegration times, and clinical studies are also discussed.
Pharmaceutical manufacturing of crude drug powder-dry compacting method with a roller compactor
- K Konishi
- H Sunada
- Y Yonezawa
- K Danjo
Konishi, K., Sunada, H., Yonezawa, Y., and Danjo, K. (2006a).
Pharmaceutical manufacturing of crude drug powder-dry
compacting method with a roller compactor. J. Pharm. Sci.
Technol. Japan, 66, 151−159.
Characterization and neuro-activation capacity of constituents of citrus peel from Ehime Prefecture
- Y Amakura
- M Yoshimura
- S Okuyama
- Y Furukawa
Amakura, Y., Yoshimura, M., Okuyama, S., and Furukawa, Y.
(2013). Characterization and neuro-activation capacity of
constituents of citrus peel from Ehime Prefecture. FFI J.,
218, 28−35.
Food and beverage containing the peel of Citrus kawachiensis
- N Fukuda
- T Tamai
- Y Furukawa
- Y Amakura
- S Okuyama
- M Yoshimura
- M Nakajima
- M Igase
- T Sugawara
- M Sudo
- K Sugawara
Fukuda, N., Tamai, T., Furukawa, Y., Amakura, Y., Okuyama,
S., Yoshimura, M., Nakajima, M., Igase, M., Sugawara, T.,
Sudo, M., and Sugawara, K. (2019). Food and beverage
containing the peel of Citrus kawachiensis. Japan Patent
Kokai, P2019-33681A, Mar. 7.
New functional labeling of health food and quality of health food
- Y Goda
Goda, Y. (2015). New functional labeling of health food and
quality of health food. J. Pharm. Sci. Technol. Japan, 75,
170−176.
Research on development of orally disintegrating tablets containing tea leaves using microwaves
- Y Iwao
- S Kimura
- S Itai
Optimization of tabletization of Kampo medicines (1)-disintegration
- S Mochizuki
- M Suzuki
- K Yano
Mochizuki, S., Suzuki, M., and Yano, K. (2005). Optimization
of tabletization of Kampo medicines (1)-disintegration.
Characterization of physicochemical properties of crospovidone (Kollidon CL grade) and its application for orally disintegrating tablet
- Y Katsuno
Pharmaceutical manufacturing of crude drug powder-crude drug granules by fluidized bed granulation
- K Konishi
- H Sunada
- Y Yonezawa
- K Danjo
Konishi, K., Sunada, H., Yonezawa, Y., and Danjo, K. (2006b).
Pharmaceutical manufacturing of crude drug powder-crude
drug granules by fluidized bed granulation. J. Pharm. Sci.
Technol. Japan, 66, 457−463.
Roller compaction and tabletting of
- S G Von Eggelkraut-Gottanka
- S A Abed
- W Muller
- P C Schmidt
von Eggelkraut-Gottanka, S.G., Abed, S.A., Muller, W., and
Schmidt, P.C. (2002). Roller compaction and tabletting of
s wort plant dry extract using a gap width and force-controlled roller compactor. I. Granulation and tabletting of eight different extract batches
- St
- John
St. John's wort plant dry extract using a gap width and
force-controlled roller compactor. I. Granulation and
tabletting of eight different extract batches. Pharm. Dev.
Technol., 7, 433−445.